In a large, nationwide cohort study involving more than 80,000 patients with type 2 diabetes and MASLD in Korea, treatment with SGLT-2 inhibitors was associated with lower incidence rates of liver-related outcomes and regression [85] of MASLD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.